Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech
Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech
$200.00
As Brexit looms and a no-deal scenario becomes increasingly a possibility, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has updated their guidance on how to respond should no deal with Europe be reached. What does it mean for Medtech? Find out here.
Author: Amanda Maxwell
Publisher: MedTech
- Description
With the possibility of a no-deal Brexit scenario becoming more likely, the Medicines and healthcare products Regulatory Agency (MHRA) in the UK has edited its guidelines for clinical trials, medical devices, and medicines, to include updates on what will change should a no-deal exit option be selected on March 29, the date set for Brexit. Find out what MHRA is recommending, how issues like potential medicines shortages will be mitigated, how registration for medical devices and IVDs will change after March 29, what a no-deal exit means for UK-based notified bodies, and more.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Germany Begins The Year With Two Possible Rx-To-OTC Switches 
Sign up to the